Advertisement

Topics

Reset Therapeutics, Inc. Company Profile

01:19 EDT 17th June 2019 | BioPortfolio

Reset, a discovery-stage biopharma company co-founded by leaders in the field of circadian biology and Bay City Capital, is developing first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. The company engineered a proprietary platform designed to identify and characterize compounds that modulate the activity and function of molecular clocks and discovers drugs that modulate these clocks and clock-controlled systems. Reset elucidates the connections between abnormal diurnal physiology and disease and has developed a burgeoning pipeline of potential new treatments that modulate these connections.


News Articles [904 Associated News Articles listed on BioPortfolio]

Sandoz, Pear Therapeutics launch reSET-O in US to treat OUD

The reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available. The reSET-O prescription digital therapeutic (PDT) is a 12-week cognitive behavioral therapy T...

Sandoz, Pear Therapeutics launch reSET-O prescription digital therapeutic in US

The reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available. The reSET-O prescription digital therapeutic (PDT) is a 12-week cognitive behavioral therapy T...

Sandoz, Pear Receive FDA Clearance For ReSET-O To Treat Opioid Use Disorder

BASEL (dpa-AFX) - Sandoz Inc., a division of Novartis (NVS), and Pear Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted clearance for reSET-O.reSET-O is intended t...

Sandoz, Pear Therapeutics launch reSET prescription digital therapeutic for SUD

Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence in substances of abuse an...

Sandoz, Pear Therapeutics get FDA nod for reSET-O mobile medical application

The reSET-O app is a prescription cognitive behavioral therapy, which is intended to enhance retention of patients with OUD in outpatient treatment. It offers cognitive behavioral therapy (CBT) The p...

Sandoz And Pear Announce US Launch Of ReSET-O To Treat Opioid Use Disorder

BASEL (dpa-AFX) - Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced the US commercial launch of reSET-O for patients with Opioid Use Disorder or OUD. reSET-O, cleared by the...

Sandoz, Pear Therapeutics introduce reSET for patients with substance use disorder

Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced the commercial launch of reSET for patients with Substance Use Disorder (SUD).

Sandoz and Pear Therapeutics Announce US Launch of reSET-O™ to Help Treat Opioid Use Disorder $NVS https://www.businesswire.com/news/home/20190107006050/en/Sandoz-Pear-Therapeutics-Announce-Launch-reSET-O%E2%84%A2-Treat …

Sandoz and Pear Therapeutics Announce US Launch of reSET-O™ to Help Treat Opioid Use Disorder $NVS https://www.businesswire.com/news/home/20190107006050/en/Sandoz-Pear-Therapeutics-Announce-La...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [501 Associated PubMed Articles listed on BioPortfolio]

Transport properties and first-arrival statistics of random motion with stochastic reset times.

Stochastic resets have lately emerged as a mechanism able to generate finite equilibrium mean-square displacement (MSD) when they are applied to diffusive motion. Furthermore, walkers with an infinite...

The Observation of Resistive Switching Characteristics using Transparent and Biocompatible Cu2+-doped Salmon DNA Composite Thin Film.

For the potential switching bio-memory device application using DNA composite thin film, we fabricated and characterized the transparent and biocompatible resistive switching random access memory (RRA...

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

: CE/HTM Professional Roles in Healthcare Delivery: Time for a Trajectory Reset?

Ultra-short burst suppression as a "reset switch" for refractory status epilepticus.

Clinical Trials [205 Associated Clinical Trials listed on BioPortfolio]

Comprehensive CBT (Cognitive Behavioral Therapy) Via reSET App

This research is being done to find out whether an app based cognitive behavior therapy called reSET improves the adherence to and outcome of buprenorphine treatment for opioid use disorde...

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure. Our proposed...

Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease

This is a study to evaluate peripheral vibrotactile coordinated reset stimulation for Parkinson's disease seeks to explore the safety and efficacy of an experimental non-invasive method to...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Companies [1341 Associated Companies listed on BioPortfolio]

Reset Therapeutics, Inc.

Reset, a discovery-stage biopharma company co-founded by leaders in the field of circadian biology and Bay City Capital, is developing first-in-class approaches to treating diseas...

Reset Therapeutics

Reset Therapeutics is a privately held biopharmaceutical company focused on harnessing the power of the body’s internal molecular clocks to discover, develop, and commerciali...

Pear Therapeutics, Inc.

Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based th...

Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approv...

American Institute of Chemical Engineers (AIChE)

AIChE is enhancing its website and database security policies which require that the security features currently in place be updated. Registered passwords will be reset on Sunday, July 8. Registered ...

More Information about "Reset Therapeutics, Inc." on BioPortfolio

We have published hundreds of Reset Therapeutics, Inc. news stories on BioPortfolio along with dozens of Reset Therapeutics, Inc. Clinical Trials and PubMed Articles about Reset Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Reset Therapeutics, Inc. Companies in our database. You can also find out about relevant Reset Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record